What You Should Know:
– Guardant Health, a provider in precision oncology, and ConcertAI, a real-world evidence (RWE) and AI technology company in oncology, announced a strategic collaboration that will provide biopharmaceutical companies with access to a first-of-its-kind multi-modal real-world data (RWD) solution.
– The partnership integrates comprehensive patient electronic medical record (EMR) data with genomic and epigenomic tumor profiling information, offering a deeper understanding of cancer biology and treatment response.
Enhanced Cancer Research and Development
Cancer is a complex disease, and a patient’s response to treatment can be influenced by various factors, including specific genetic mutations, prior therapies, and the development of drug resistance. This new joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma researchers to:
- Better interpret disease biology: Gain a more comprehensive understanding of the underlying mechanisms driving cancer progression.
- Identify drivers of tumor evolution: Pinpoint the specific genetic and epigenetic changes that contribute to tumor growth and spread.
- Understand resistance mechanisms: Uncover how tumors develop resistance to therapies, both intrinsically and over time.
By leveraging this comprehensive dataset, combined with the analytics capabilities and AI SaaS solutions of both ConcertAI and Guardant Health, biopharmaceutical companies can gain a deeper understanding of cancer and develop more effective treatments.
“Realizing the potential of precision medicine requires a comprehensive, multi-dimensional understanding of the tumor, the clinical environment and the patient’s response to therapy,” said Helmy Eltoukhy, Guardant Health co-CEO. “This partnership between Guardant and ConcertAI gives evidence and outcomes researchers access to extensive, robust data and AI-based modeling that can provide unprecedented insight into a patient’s cancer journey, including a tumor’s complex systemic interactions, to help them accelerate the development of much-needed cancer therapies. It represents another milestone in Guardant’s mission to conquer cancer with data.”
